11/25
04:40 pm
phge
BiomX Provides Update on BX004 Phase 2b Trial in Cystic Fibrosis
High
Report
BiomX Provides Update on BX004 Phase 2b Trial in Cystic Fibrosis
11/14
04:31 pm
phge
BiomX Inc. Announces 1-for-19 Reverse Stock Split
Medium
Report
BiomX Inc. Announces 1-for-19 Reverse Stock Split
11/12
04:32 pm
phge
BiomX Inc (PHGE) Q3 2025 Earnings Call Highlights: Strategic Advances Amid Financial Challenges [Yahoo! Finance]
Medium
Report
BiomX Inc (PHGE) Q3 2025 Earnings Call Highlights: Strategic Advances Amid Financial Challenges [Yahoo! Finance]
11/12
10:38 am
phge
BiomX outlines imminent FDA feedback and targets BX004 Phase IIb data in Q1 2026 while advancing BX011 for diabetic foot infections [Seeking Alpha]
Medium
Report
BiomX outlines imminent FDA feedback and targets BX004 Phase IIb data in Q1 2026 while advancing BX011 for diabetic foot infections [Seeking Alpha]
11/12
10:32 am
phge
BiomX Inc. (PHGE) Q3 2025 Earnings Call Transcript [Seeking Alpha]
Medium
Report
BiomX Inc. (PHGE) Q3 2025 Earnings Call Transcript [Seeking Alpha]
11/12
08:21 am
phge
BiomX Reports Third Quarter 2025 Financial Results and Provides Program Updates [Yahoo! Finance]
Medium
Report
BiomX Reports Third Quarter 2025 Financial Results and Provides Program Updates [Yahoo! Finance]
11/12
07:30 am
phge
BiomX Reports Third Quarter 2025 Financial Results and Provides Program Updates
Low
Report
BiomX Reports Third Quarter 2025 Financial Results and Provides Program Updates
11/5
08:30 am
phge
BiomX to Report Third Quarter 2025 Financial Results and Program Updates on November 12, 2025
Medium
Report
BiomX to Report Third Quarter 2025 Financial Results and Program Updates on November 12, 2025
11/4
08:40 am
phge
BiomX Announces Positive FDA Feedback Supporting Next-Generation Phage Cocktail Program for Diabetic Foot Infections
High
Report
BiomX Announces Positive FDA Feedback Supporting Next-Generation Phage Cocktail Program for Diabetic Foot Infections
10/17
08:30 am
phge
BiomX Provides a Program Update and Announces New FDA Feedback Potentially Expanding BX004 Development Pathways
Low
Report
BiomX Provides a Program Update and Announces New FDA Feedback Potentially Expanding BX004 Development Pathways